<p>Athira Pharma, Inc.（纳斯达克股票代码：ATHA - 获取免费报告）在六月份看到了空头头寸的显著增长。截至 6 月 15 日，空头头寸总计为 1,010,000 股，比 5 月 31 日的 889,500 股增长了 13.5%。基于平均每日交易量为 173,900 股，目前的空头头寸比率为 5.8 天。目前，该股的 2.9% 股份被空头卖空。</p>
<p>获取 <strong>Athira Pharma</strong> 警报：</p>
<h2>Athira Pharma 交易上涨 0.4%</h2>
<ul>
<li>这些生物技术公司致力于多种神经退行性疾病</li>
</ul>
<p>ATHA 股票周一开盘价为$2.65。该股市值为$1.0157 亿，市盈率为-0.87，β值为 2.91。Athira Pharma 的 12 个月最低价为$1.33，最高价为$4.30。该公司的 50 天移动平均价格为$2.37，200 天移动平均价格为$2.72。</p>
<p>Athira Pharma（纳斯达克股票代码：ATHA - 获取免费报告）上次公布财报是在 5 月 15 日星期三。公司报告该季度每股亏损 ($0.69)，超过分析师预期的 ($0.80) $0.11。卖方分析师预测，Athira Pharma 今年将发布-2.79 美元的每股收益。</p>
<h2>内部交易</h2>
<p>在其他 Athira Pharma 新闻中，董事 Kelly A. Romano 于 6 月 24 日星期一以每股$2.42 的平均价格收购了公司的 27,400 股股票。购买后，该董事现在直接持有公司 80,715 股股票，价值约$195,330.30。这笔交易已在美国证券交易委员会（SEC）的法律文件中披露。此外，Kelly A. Romano 董事于 6 月 24 日星期一以每股$2.42 的平均价格购买了 27,400 股 Athira Pharma 股票，总价值为$66,308.00。购买后，该董事现在持有公司 80,715 股股票，价值为$195,330.30。这笔交易已在美国证券交易委员会的文件中披露，可通过此链接访问。此外，Kelly A. Romano 董事于 6 月 21 日星期五以每股$2.26 的平均价格购买了 15,000 股 Athira Pharma 股票，总交易额为$33,900.00。购买完成后，该董事现在直接持有公司 53,315 股股票，价值$120,491.90。有关此次购买的披露可在此处找到。目前，19.80% 的股份由公司内部持有。</p>
<h2>Athira Pharma 的机构交易</h2>
<p>一些对冲基金和其他机构投资者最近买入和卖出了该公司的股票。Jacobs Levy Equity Management Inc.在第一季度将其在 Athira Pharma 的持股增加了 84.1%。Jacobs Levy Equity Management Inc.现在拥有公司 497,475 股股票，价值$1,363,000，较之前增加了 227,278 股。Acadian Asset Management LLC 在第一季度将其在 Athira Pharma 的持仓增加了 281.5%。Acadian Asset Management LLC 现在拥有公司 549,938 股股票，价值$1,505,000，较之前增加了 405,793 股。Mirador Capital Partners LP 在第一季度购入了 Athira Pharma 的新股份，价值约$57,000。Perceptive Advisors LLC 在第四季度将其在 Athira Pharma 的持股增加了 12.6%。Perceptive Advisors LLC 现在拥有公司 5,402,964 股股票，价值$13,129,000，较之前增加了 605,686 股。最后，Forefront Analytics LLC 在第四季度将其在 Athira Pharma 的持股增加了 43.0%。Forefront Analytics LLC 现在拥有公司 29,765 股股票，价值$72,000，较之前增加了 8,955 股。对冲基金和其他机构投资者拥有公司 57.12% 的股份。</p>
<h2>分析师评级变动</h2>
<p>另外，JMP Securities 重申了对 Athira Pharma 股票的&#34;市场表现优异&#34;评级，并在 6 月 20 日星期四的研究报告中给出了$19.00 的目标价。</p>
<p><strong>查看我们对 ATHA 的最新分析</strong></p>
<h2>关于 Athira Pharma（获取免费报告）</h2>
<p>Athira Pharma, Inc 是一家晚期临床阶段的生物制药公司，专注于开发小分子药物以恢复神经健康并减缓神经退化。其主要产品候选药物是 Fosgonimeton（ATH-1017），这是一种小分子药物，旨在调节神经营养肝细胞生长因子（HGF）系统及其受体 MET，用于治疗阿尔茨海默病的 LIFT-AD 第 2/3 期和 ACT-AD 第 2 期临床试验，以及用于治疗帕金森病痴呆和带有 Lewy 小体的第 2 期临床试验。</p>
<h2>精选故事</h2>
<ul>
<li>我们喜欢的五只股票胜过 Athira Pharma</li>
<li>金叉股票：模式、示例和图表</li>
<li>Upwork 股票展望：尽管面临 Gen-AI 挑战，数字仍稳健</li>
<li>在购买股票之前如何评估一家公司</li>
<li>瓦尔格林股票暴跌背后的原因：投资者下一步该怎么做</li>
<li>什么是 MarketRank™？如何使用</li>
<li>MarketBeat 周评 - 6/24 - 6/28</li>
</ul>
<p><em>此即时新闻警报由 Narrative Science 技术和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 年轻亿万富翁为数百万美国人打开大门（来自 Porter &amp; Company）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTk0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTk0"/></p>
<h2>现在是否值得投资$1,000 在 Athira Pharma？</h2>
<p>在考虑 Athira Pharma 之前，您会想听听这个。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票，然后等待整个市场的关注... 而 Athira Pharma 并不在这份名单上。</p>
<p>虽然 Athira Pharma 目前在分析师中有一个 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ATHA

LONA

<p>Athira Pharma（纳斯达克股票代码：ATHA）在六月份看到空头头寸显著增加，共计 1,010,000 股，比五月份增长了 13.5%。该股目前的偿付天数比率为 5.8，有 2.9% 的股份被卖空。此外，董事 Kelly A. Romano 购入了该公司股票。对冲基金和机构投资者也积极参与了 Athira Pharma 股票的交易</p>

<p>Athira Pharma, Inc. (NASDAQ:ATHA - Get Free Report) saw a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 1,010,000 shares, a growth of 13.5% from the May 31st total of 889,500 shares. Based on an average daily volume of 173,900 shares, the short-interest ratio is currently 5.8 days. Currently, 2.9% of the shares of the stock are short sold.</p>
<div class="lb-trans"><p>Athira Pharma, Inc.（纳斯达克股票代码：ATHA - 获取免费报告）在六月份看到了空头头寸的显著增长。截至 6 月 15 日，空头头寸总计为 1,010,000 股，比 5 月 31 日的 889,500 股增长了 13.5%。基于平均每日交易量为 173,900 股，目前的空头头寸比率为 5.8 天。目前，该股的 2.9% 股份被空头卖空。</p>
</div><p>Get <strong>Athira Pharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Athira Pharma</strong> 警报：</p>
</div><h2>Athira Pharma Trading Up 0.4 %</h2>
<ul>
<li>These biotechs targeting multiple neurodegenerative diseases</li>
</ul>
<div class="lb-trans"><h2>Athira Pharma 交易上涨 0.4%</h2>
<ul>
<li>这些生物技术公司致力于多种神经退行性疾病</li>
</ul>
</div><p>ATHA stock opened at $2.65 on Monday. The stock has a market cap of $101.57 million, a PE ratio of -0.87 and a beta of 2.91. Athira Pharma has a 12 month low of $1.33 and a 12 month high of $4.30. The company has a 50-day moving average price of $2.37 and a 200 day moving average price of $2.72.</p>
<div class="lb-trans"><p>ATHA 股票周一开盘价为$2.65。该股市值为$1.0157 亿，市盈率为-0.87，β值为 2.91。Athira Pharma 的 12 个月最低价为$1.33，最高价为$4.30。该公司的 50 天移动平均价格为$2.37，200 天移动平均价格为$2.72。</p>
</div><p>Athira Pharma (NASDAQ:ATHA - Get Free Report) last released its earnings results on Wednesday, May 15th. The company reported ($0.69) EPS for the quarter, beating analysts' consensus estimates of ($0.80) by $0.11. Sell-side analysts forecast that Athira Pharma will post -2.79 EPS for the current year.</p>
<div class="lb-trans"><p>Athira Pharma（纳斯达克股票代码：ATHA - 获取免费报告）上次公布财报是在 5 月 15 日星期三。公司报告该季度每股亏损 ($0.69)，超过分析师预期的 ($0.80) $0.11。卖方分析师预测，Athira Pharma 今年将发布-2.79 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部交易</h2>
</div><p>In other Athira Pharma news, Director Kelly A. Romano acquired 27,400 shares of the company's stock in a transaction on Monday, June 24th. The stock was acquired at an average cost of $2.42 per share, with a total value of $66,308.00. Following the purchase, the director now directly owns 80,715 shares of the company's stock, valued at approximately $195,330.30. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Athira Pharma news, Director Kelly A. Romano purchased 27,400 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was purchased at an average price of $2.42 per share, with a total value of $66,308.00. Following the acquisition, the director now owns 80,715 shares in the company, valued at $195,330.30. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, Director Kelly A. Romano acquired 15,000 shares of Athira Pharma stock in a transaction on Friday, June 21st. The shares were bought at an average cost of $2.26 per share, for a total transaction of $33,900.00. Following the completion of the purchase, the director now directly owns 53,315 shares of the company's stock, valued at $120,491.90. The disclosure for this purchase can be found here. 19.80% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Athira Pharma 新闻中，董事 Kelly A. Romano 于 6 月 24 日星期一以每股$2.42 的平均价格收购了公司的 27,400 股股票。购买后，该董事现在直接持有公司 80,715 股股票，价值约$195,330.30。这笔交易已在美国证券交易委员会（SEC）的法律文件中披露。此外，Kelly A. Romano 董事于 6 月 24 日星期一以每股$2.42 的平均价格购买了 27,400 股 Athira Pharma 股票，总价值为$66,308.00。购买后，该董事现在持有公司 80,715 股股票，价值为$195,330.30。这笔交易已在美国证券交易委员会的文件中披露，可通过此链接访问。此外，Kelly A. Romano 董事于 6 月 21 日星期五以每股$2.26 的平均价格购买了 15,000 股 Athira Pharma 股票，总交易额为$33,900.00。购买完成后，该董事现在直接持有公司 53,315 股股票，价值$120,491.90。有关此次购买的披露可在此处找到。目前，19.80% 的股份由公司内部持有。</p>
</div><h2>Institutional Trading of Athira Pharma</h2>
<div class="lb-trans"><h2>Athira Pharma 的机构交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Jacobs Levy Equity Management Inc. increased its stake in Athira Pharma by 84.1% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 497,475 shares of the company's stock worth $1,363,000 after buying an additional 227,278 shares during the period. Acadian Asset Management LLC increased its position in shares of Athira Pharma by 281.5% during the first quarter. Acadian Asset Management LLC now owns 549,938 shares of the company's stock worth $1,505,000 after acquiring an additional 405,793 shares during the period. Mirador Capital Partners LP bought a new stake in shares of Athira Pharma during the first quarter valued at approximately $57,000. Perceptive Advisors LLC boosted its holdings in shares of Athira Pharma by 12.6% in the fourth quarter. Perceptive Advisors LLC now owns 5,402,964 shares of the company's stock valued at $13,129,000 after purchasing an additional 605,686 shares during the period. Finally, Forefront Analytics LLC grew its stake in Athira Pharma by 43.0% in the fourth quarter. Forefront Analytics LLC now owns 29,765 shares of the company's stock worth $72,000 after purchasing an additional 8,955 shares in the last quarter. Hedge funds and other institutional investors own 57.12% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近买入和卖出了该公司的股票。Jacobs Levy Equity Management Inc.在第一季度将其在 Athira Pharma 的持股增加了 84.1%。Jacobs Levy Equity Management Inc.现在拥有公司 497,475 股股票，价值$1,363,000，较之前增加了 227,278 股。Acadian Asset Management LLC 在第一季度将其在 Athira Pharma 的持仓增加了 281.5%。Acadian Asset Management LLC 现在拥有公司 549,938 股股票，价值$1,505,000，较之前增加了 405,793 股。Mirador Capital Partners LP 在第一季度购入了 Athira Pharma 的新股份，价值约$57,000。Perceptive Advisors LLC 在第四季度将其在 Athira Pharma 的持股增加了 12.6%。Perceptive Advisors LLC 现在拥有公司 5,402,964 股股票，价值$13,129,000，较之前增加了 605,686 股。最后，Forefront Analytics LLC 在第四季度将其在 Athira Pharma 的持股增加了 43.0%。Forefront Analytics LLC 现在拥有公司 29,765 股股票，价值$72,000，较之前增加了 8,955 股。对冲基金和其他机构投资者拥有公司 57.12% 的股份。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Separately, JMP Securities restated a &#34;market outperform&#34; rating and issued a $19.00 price target on shares of Athira Pharma in a research report on Thursday, June 20th.</p>
<div class="lb-trans"><p>另外，JMP Securities 重申了对 Athira Pharma 股票的&#34;市场表现优异&#34;评级，并在 6 月 20 日星期四的研究报告中给出了$19.00 的目标价。</p>
</div><p><strong>Check Out Our Latest Analysis on ATHA</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ATHA 的最新分析</strong></p>
</div><h2>About Athira Pharma (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 Athira Pharma（获取免费报告）</h2>
</div><p>Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.</p>
<div class="lb-trans"><p>Athira Pharma, Inc 是一家晚期临床阶段的生物制药公司，专注于开发小分子药物以恢复神经健康并减缓神经退化。其主要产品候选药物是 Fosgonimeton（ATH-1017），这是一种小分子药物，旨在调节神经营养肝细胞生长因子（HGF）系统及其受体 MET，用于治疗阿尔茨海默病的 LIFT-AD 第 2/3 期和 ACT-AD 第 2 期临床试验，以及用于治疗帕金森病痴呆和带有 Lewy 小体的第 2 期临床试验。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Athira Pharma</li>
<li>Golden Cross Stocks: Pattern, Examples and Charts</li>
<li>Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges</li>
<li>How to Evaluate a Stock Before Buying</li>
<li>What's Behind Walgreens Stock Plunge: What Investors Can Do Next</li>
<li>What is MarketRank™? How to Use it</li>
<li>MarketBeat Week in Review – 6/24 - 6/28</li>
</ul>
<div class="lb-trans"><h2>精选故事</h2>
<ul>
<li>我们喜欢的五只股票胜过 Athira Pharma</li>
<li>金叉股票：模式、示例和图表</li>
<li>Upwork 股票展望：尽管面临 Gen-AI 挑战，数字仍稳健</li>
<li>在购买股票之前如何评估一家公司</li>
<li>瓦尔格林股票暴跌背后的原因：投资者下一步该怎么做</li>
<li>什么是 MarketRank™？如何使用</li>
<li>MarketBeat 周评 - 6/24 - 6/28</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由 Narrative Science 技术和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Young billionaire opens the door for millions of Americans (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 年轻亿万富翁为数百万美国人打开大门（来自 Porter &amp; Company）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTk0" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8594&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Athira Pharma right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 在 Athira Pharma？</h2>
</div><p>Before you consider Athira Pharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Athira Pharma 之前，您会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Athira Pharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票，然后等待整个市场的关注... 而 Athira Pharma 并不在这份名单上。</p>
</div><p>While Athira Pharma currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Athira Pharma 目前在分析师中有一个 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Athira Pharma 公司（NASDAQ:ATHA）空头头寸更新